Evidence supporting the use of: Protease Inhibitors
For the health condition: Hepatitis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Protease inhibitors are scientifically validated as a cornerstone in the treatment of certain forms of viral hepatitis, particularly hepatitis C. These drugs specifically target and inhibit the function of viral protease enzymes, which are essential for the replication and maturation of the hepatitis C virus (HCV). By blocking these enzymes, protease inhibitors prevent the virus from multiplying and assembling properly, thereby reducing viral load in the patient's body. Clinical trials and extensive research have demonstrated the efficacy of protease inhibitors—such as boceprevir, telaprevir, simeprevir, and others—as part of direct-acting antiviral (DAA) regimens. The introduction of these agents has dramatically improved sustained virological response (SVR) rates, often achieving cure rates above 90% when combined with other antiviral medications. The use of protease inhibitors has transformed hepatitis C from a chronic, potentially life-threatening disease into one that is routinely curable. There is little to no role for protease inhibitors in the treatment of hepatitis B, as the virus relies on different enzymes for replication. Their use is not based on tradition, but rather on robust scientific evidence, clinical trials, and guidelines established by major liver disease and infectious disease organizations.

More about Protease Inhibitors
More about Hepatitis

Other health conditions supported by Protease Inhibitors

Acquired Immune Deficiency Syndrome
Hepatitis
Infection (viral)

Products containing Protease Inhibitors

We currently have no products on Vitabase that contain this ingredient.